Status:
COMPLETED
Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Tachycardia
Eligibility:
All Genders
65-90 years
Phase:
PHASE4
Brief Summary
The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and...
Eligibility Criteria
Inclusion
- Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux
- Patient able to give informed consent, and sign the consent.
Exclusion
- Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction
- Morbid obesity (Body Mass Index \> 40)
- Emergency situation with unstable hemodynamics, and stabilization is impossible before induction
- Inclusion in another research project within the past 3 months
- The patient is not insured or beneficiary of a health insurance plan (for the French centers)
- Patient under guardianship of any kind
- Patient unable to give informed consent
- Refusal to sign the consent form
Key Trial Info
Start Date :
March 9 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2014
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01259648
Start Date
March 9 2011
End Date
May 20 2014
Last Update
November 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Nîmes
Nîmes, Gard, France, 30029
2
Polyclinique Grand Sud
Nîmes, Gard, France, 30029